Access Dermatology

Breaking News

• Home »
• Breaking News »
• Breaking News article

Topical WBI-1001 improves atopic dermatitis in double-blind trial

Significant improvements in various atopic dermatitis efficacy assessments were seen with WBI-1001 in a randomized, double-blind, vehicle-controlled study. The 37 enrolled patients applied twice-daily WBI-1001 0.5%, WBI-1001 1.0% or vehicle cream for 4 weeks. Respective reductions in the groups receiving WBI-1001 0.5%, WBI-1001 1.0% and vehicle were 59.3, 54.9 and 7.1% for Eczema Area Severity Index scores; 56.2, 50.1 and 18.4% for Scoring Atopic Dermatitis Severity Index scores; 38.9, 45.8 and 5.6% for the Investigator Global Assessments; 64.4, 57.7 and 1.08% for the percentage of body surface area affected; and 74.0, 56.0 and 25.0% for pruritus scores. In addition, half of the WBI-1001-treated patients were clear or almost clear at week ...